Join +750K new investors every month who copy stock picks from billionaire's portfoliosSign Up Free

Teva to launch generic version of EpiPen for young children

Published 2019-08-20, 08:23 a/m
© Reuters.  Teva to launch generic version of EpiPen for young children
TEVA
-
PFE
-
TEVA
-
VTRS
-

Aug 20 (Reuters) - Teva Pharmaceutical Industries (NYSE:TEVA) Ltd TEVA.TA said on Tuesday its generic version of Mylan's MYL.O EpiPen for young children will be available in most retail pharmacies at a price of $300 for a 2-pack.

Israel-based Teva TEVA.N , the world's largest generic drugmaker, is already selling the product for adults, after getting U.S. approval for its copy of EpiPen in August following several years of delay.

Mylan also produces a generic version of its own life-saving EpiPen allergy treatment, which like Teva's product is priced at about $300.

There has been a shortage of EpiPens in the United States, Europe and Canada, mainly due to a series of manufacturing delays at Pfizer (NYSE:PFE) Inc's PFE.N Meridian Medical unit that produces all EpiPens sold globally at a single plant near St. Louis.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.